Gene:
CYP2C8
cytochrome P450, family 2, subfamily C, polypeptide 8

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all CYP2C8 variant annotations

Variant?
(142)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA *1A N/A N/A N/A
No VIP available CA VA *2 N/A N/A N/A
No VIP available CA VA *3 N/A N/A N/A
No VIP available No VIP available VA *4 N/A N/A N/A
rs10509681 1196A>G, 35506A>G, 47603213T>C, 890A>G, 96798749T>C, 986A>G, A1196G, CYP2C8*3, CYP2C8: K399R, Lys297Arg, Lys329Arg, Lys399Arg
T > C
Missense
Lys329Arg
rs1058930 16136C>G, 47622583G>C, 486C>G, 582C>G, 792C>G, 96818119G>C, C792G, CYP2C8: I264M, Ile162Met, Ile194Met, Ile264Met
G > C
Missense
Ile194Met
No VIP available CA VA
rs1113129 23210C>G, 47615509G>C, 514-5337C>G, 610-5337C>G, 820-5337C>G, 96811045G>C, CYP2C8-HapC, Haplotype low act, rs1113129 G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs11572076 122-36G>A, 26-36G>A, 332-36G>A, 47631614C>T, 7105G>A, 96827150C>T
C > T
Intronic
rs11572080 110G>A, 206G>A, 416G>A, 47631494C>T, 7225G>A, 96827030C>T, Arg139Lys, Arg37Lys, Arg69Lys, CYP2C8*3, CYP2C8: R139K, G416A, R139K, rs11572080 G>A
C > T
Missense
Arg69Lys
rs11572103 16149A>T, 47622570T>A, 499A>T, 595A>T, 805A>T, 96818106T>A, A805T, CYP2C8*2, CYP2C8: I269F, Ile167Phe, Ile199Phe, Ile269Phe
T > A
Missense
Ile199Phe
VIP No Clinical Annotations available No Variant Annotations available
rs17110453 -370T>G, -551T>G, -618T>G, -680T>G, 4726T>G, 47633993A>C, 96829529A>C
A > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs193451 108310986A>G, 46343829A>G
A > G
Not Available
No VIP available CA VA
rs1934951 1081+106G>A, 1291+106G>A, 35707G>A, 47603012C>T, 96798548C>T, 985+106G>A
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs2275622 122-64A>G, 26-64A>G, 332-64A>G, 47631642T>C, 7077A>G, 96827178T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs66501115 1000C>G, 1210C>G, 35520C>G, 47603199G>C, 904C>G, 96798735G>C, Pro302Ala, Pro334Ala, Pro404Ala
G > C
Missense
Pro334Ala
VIP No Clinical Annotations available No Variant Annotations available
rs7909236 -271C>A, -452C>A, -519C>A, -581C>A, 47633894G>T, 4825C>A, 96829430G>T
G > T
5' Flanking
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 142

Overview

Alternate Names:  None
Alternate Symbols:  CPC8
PharmGKB Accession Id: PA125

Details

Cytogenetic Location: chr10 : q23.33 - q23.33
GP mRNA Boundary: chr10 : 96796529 - 96829254
GP Gene Boundary: chr10 : 96793529 - 96839254
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Introduction
Cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) is a phase I metabolizing enzyme that plays an integral role in the biotransformation of structurally diverse xenobiotics and endogenous compounds [Article:7704034]. CYP2C8 accounts for 7% of CYP content in the liver, and is expressed to a lesser extent in the kidney, adrenal gland, mammary gland, brain, ovary, uterus, and duodenum [Articles:8035341, 9187528, 15900280, 10487415]. Over the last decade, CYP2C8 has garnered increased attention following the elucidation of its crystal structure, identification of clinically relevant substrates and inhibitors, and characterization of functional CYP2C8 single nucleotide polymorphisms (SNPs). This PharmGKB summary discusses CYP2C8 and its pharmacogenomic importance.

Substrates, inhibitors, and inducers
CYP2C8 is responsible for the biotransformation of 5% of currently used drugs that undergo phase I hepatic metabolism [Article:15900280]. The enzyme's substrate-binding cavity can accommodate large and structurally unrelated compounds (e.g., paclitaxel, amiodarone) [Articles:14676196, 18413310]. In addition, the CYP2C8 active site is similar in size, but different in shape, to CYP3A4 [Articles:14676196, 15258162]. This likely explains why CYP2C8 and CYP3A4 often have overlapping substrates, but yield different metabolite profiles [Articles:15900280, 16157296].
CYP2C8 also plays an intermediate or minor role in the oxidation of myriad other xenobiotics and endogenous compounds such as NSAIDs (e.g., ibuprofen, diclofenac) [Articles:9296349, 10449188], statins (e.g., fluvastatin, simvastatin acid) [Articles:10064574, 12848784], calcium channel blockers (e.g., verapamil) [Articles:8750925, 10336579], opioids (e.g., morphine, methadone) [Articles:12936704, 12756206], tyrosine kinase inhibitors (e.g., imatinib) [Articles:20977456, 23028140], arachidonic acid [Articles:7625847, 7574697], retinoids [Articles:2916844, 10484078, 10874126, 11093772], and others. Further information regarding CYP2C8 substrates is provided at http://medicine.iupui.edu/clinpharm/ddis/table.aspx and in these comprehensive reviews [Articles:15900280, 19761371, 20214592].

In vitro, many compounds have been shown to inhibit CYP2C8 including gemfibrozil, trimethoprim, ketoconazole, montelukast, quercetin, and others [Articles:7923194, 11136296, 12019187, 12433802, 12868554, 15601807]. In vivo, gemfibrozil is the most potent CYP2C8 inhibitor, primarily due to rapid, mechanism-based inactivation of CYP2C8 by its 1-O-ß glucuronide metabolite [Articles:15194707, 16299161, 19445523, 22472994, 21368757]. In clinical studies, gemfibrozil has been shown to increase the plasma exposure of CYP2C8 substrates such as rosiglitazone [Article:12898007], pioglitazone [Articles:15900286, 16283275], repaglinide [Articles:12687332, 18388877, 21778352], cerivastatin [Article:12496749], loperamide [Article:16758263], R-ibuprofen [Article:17333159], and montelukast [Article:20592724].

CYP2C8 has been described as the most inducible member of the CYP2C subfamily [Articles:15900280, 20214592]. Transcriptional activation of CYP2C8 is mediated by the pregnane X receptor (PXR, NR1I2), constitutive androstane receptor (CAR, NR1I3), and glucocorticoid receptor (GR, NR3C1) [Articles:15933212, 19702536]. Along these lines, a CAR/PXR-binding sequence in the distal promoter (-8806 bp) is thought to play a key role in CYP2C8 induction [Article:15933212]. In vitro, CYP2C8 is upregulated by the inducers rifampin (rifampicin), dexamethasone, and phenobarbital [Articles:11181490, 11714868, 12130704, 12642468]. In clinical drug-drug interaction studies, rifampin has been shown to decrease the plasma exposure of major CYP2C8 substrates such as rosiglitazone [Articles:15371985, 15001966], pioglitazone [Article:16390353], and repaglinide [Articles:11103752, 15034704].

CYP2C8 gene and common variants
CYP2C8 is located on chromosome 10q24 in a CYP2C gene cluster (centromere-CYP2C18-CYP2C19-CYP2C9-CYP2C8-telomere), of which CYP2C8 is the smallest gene (31 kb, 9 exons) [Articles:10487415, 7841444, 8530044]. Given the close proximity of CYP2C8 and CYP2C9, some linkage disequilibrium exists between these genes [Article:12435384]. Substantial interindividual variability exists in CYP2C8 protein expression and catalytic activity [Articles:20190184, 7473140, 10510156]. This variability is due, in part, to genetic polymorphisms. Over 450 CYP2C8 single nucleotide polymorphisms (SNPs) have been identified to date [Article:20214592]. Some of these SNPs, particularly those in the coding region, are associated with variability in CYP2C8-mediated metabolism and altered drug disposition and response. In general, polymorphic CYP2C8 alleles have not been assigned an activity level or phenotype classification (e.g., poor metabolizer). This is primarily due to still relatively limited in vitro data, with conflicting results; substrate-dependent functional consequences; and discrepancies between in vitro and in vivo findings. CYP2C8*1 (or *1A) refers to the wild-type or reference allele [Article:10487415]. In general, most CYP2C8 studies have only evaluated individual SNPs, referred to by * alleles. The -271C>A SNP (rs7909236) is designated as CYP2C8*1B and is present in about 23% of Whites, 10% of Asians, and is absent in Africans [Article:12429347]. The -370G>T SNP (rs17110453) is designated as CYP2C8*1C and is present in about 12% of Whites, 28-34% of Asians, and is rare in Africans [Article:12429347]. rs11572103 is designated as CYP2C8*2 and is located in exon 5. CYP2C8*2 is common in Africans (19%), but is rare in Whites and Asians [Article:11668219]. CYP2C8*3 denotes two highly linked variants, rs11572080 and rs10509681, in exons 3 and 8, respectively [Article:11668219]. rs1058930 (c.792C>G; p.I264M) is designated as CYP2C8*4 and is located in exon 5.

Rare variants
CYP2C8*5 through CYP2C8*14 are rare variants that are typically found in less than 1% of the population, mainly Asians (http://www.cypalleles.ki.se/cyp2c8.htm) [Article:15716363]. Some of these variants have demonstrated functional consequences in vitro. CYP2C8*5 (rs72558196, c.475delA, exon 3) causes a frame-shift which results in a premature stop codon at position 177 [Article:15618689]. rs72558195 is a triallelic SNP in exon 4 which results in a premature stop codon (CYP2C8*7, R186X), or an Arg to Gly at codon 186 (CYP2C8*8) [Article:15716363]. Decreased rosiglitazone hydroxylation has been reported for the CYP2C8*11 loss-of-function variant (p.E274X, exon 6) [Article:21245287]. CYP2C8*14 (p.A238P, exon 5) results in decreased paclitaxel binding affinity and decreased intrinsic clearance of amiodarone [Articles:17558302, 20148860, 21214863]. The unassigned p.P404A SNP (c.1210C>G, exon 8) has been associated with reduced protein expression and less efficient metabolism of paclitaxel and amiodarone [Articles:11767116, 12530467, 20848147]. The contribution of CYP2C8*5 through CYP2C8*14, and other rare CYP2C8 variants, to variability in clinical drug response or rare adverse drug reactions is not known.

CYP2C8 haplotype blocks
Although most CYP2C8 studies have focused on individual SNPs, some work has been done to characterize CYP2C8 haplotypes and their impact on substrate disposition. One study used HapMap data to identify CYP2C8 tag SNPs in Whites. The authors found that CYP2C8 was contained in one haplotype block (40 kb) and six tag SNPs revealed seven common haplotypes (i.e., A, B, C1, C2, C3, D, and E) with a frequency greater than 2% [Article:17923851]. Haplotype B (which contains g.-271 C>A) was associated with increased paclitaxel metabolism, while haplotype C (which combines C1, C2, and C3) was associated with decreased paclitaxel metabolism in vitro [Article:17923851]. Carriers of haplotype B or haplotype D (which contains CYP2C8*3) had lower repaglinide plasma exposure, while carriers of haplotype C had higher repaglinide plasma exposure, as compared with noncarriers [Article:17923851]. CYP2C8 haplotype structure has also been characterized in other populations (e.g., Japanese) [Articles:17558302, 21375401]. Given the close proximity of CYP2C8 to other CYP2C genes, some groups have characterized haplotypes containing variants across several genes in the CYP2C cluster [Articles:19381162, 20665013, 15608640, 21173785, 22476388, 22491019].

Clinical associations between CYP2C8 variant alleles and drug disposition, response, and toxicity

Antidiabetic agents
The thiazolidinediones, rosiglitazone and pioglitazone, are peroxisome proliferator-activated receptor- agonists that are used in the treatment of type 2 diabetes. Most healthy volunteer studies have found CYP2C8*3 to be associated with higher oral clearance and lower plasma exposure of rosiglitazone and pioglitazone as compared with wild-type homozygotes [Articles:17913794, 17178266, 19129086, 22625877, 23370354]. In terms of clinical outcomes, a recent study showed that CYP2C8*3 carriers had lower rosiglitazone trough concentrations, reduced therapeutic response, and lower risk of developing edema, as compared with CYP2C8*1/*1 individuals [Article:23426382].

Repaglinide, a nonsulfonylurea insulin secretagogue, is used to lower postprandial glucose levels in patients with type 2 diabetes. Some clinical studies have reported higher oral clearance and lower plasma exposure of subclinical doses of repaglinide in CYP2C8*3 carriers versus wild-type homozygotes [Articles:18388877, 15961978, 14534525]. However, others have shown no association between CYP2C8*3 and repaglinide pharmacokinetics or pharmacodynamics at clinically relevant doses [Articles:16390351, 21270106].

Paclitaxel
Paclitaxel is chemotherapeutic agent that is used to treat breast, lung, and ovarian malignancies. Most, but not all, clinical reports suggest that CYP2C8*3 is not a major determinant of paclitaxel pharmacokinetics [Articles:16299241, 17224914, 17925548, 19143748, 20368717]. The discrepancy between in vitro and in vivo findings is likely a result of the contribution of drug transporters to paclitaxel disposition in humans [Article:23215890]. Peripheral neuropathy is a troubling toxicity associated with paclitaxel therapy and is correlated with drug exposure [Articles:19143748, 16000582]. Some studies have reported an association between CYP2C8*3 and an increased risk of paclitaxel neurotoxicity [Articles:19143748, 20212519, 22527101, 23413280]. Additional work is needed to elucidate the clinical utility of CYP2C8 variants as predictors of neurotoxicity, and other toxicities (e.g., myelosuppression), in paclitaxel-treated patients.

Statins
Cerivastatin, an HMG-CoA reductase inhibitor and CYP2C8 substrate, was withdrawn from the market in 2001 due to a high incidence of rhabdomyolysis [Article:11844864]. It is feasible that rare, loss-of-function CYP2C8 variants (e.g., *5, *7, *11) may have predisposed some individuals to this adverse effect [Articles:20739906, 15365880]. For example, CYP2C8*5 was identified in a Japanese individual who had rhabdomyolysis following cerivastatin therapy [Article:15365880]. For other statins, no relationship has been observed between CYP2C8 polymorphisms and fluvastatin pharmacokinetics [Article:12891229] or simvastatin-induced myotoxicity [Article:18650507].

Antimalarial agents
Amodiaquine and chloroquine are used in the treatment of malaria, particularly in Africa. Although CYP2C8*2 has been associated with decreased amodiaquine metabolism in vitro, it was not a predictor of amodiaquine efficacy or major toxicities in African patients [Article:17361129]. More recently, other data suggest that host CYP2C8 variants (e.g., *2 or *3) may influence the risk of amodiaquine- or chloroquine-resistant malaria parasites [Articles:21998472, 23204183]. The potential role of CYP2C8 genetics in host-pathogen interactions and resistance merits further investigation.

Nonsteroidal anti-inflammatory drugs (NSAIDs)
Conflicting data exist regarding the relationship between CYP2C8*3 and interindividual variability in R- and S-ibuprofen pharmacokinetics [Articles:15289789, 15606441, 18694831, 19480553]. This is likely due to ibuprofen being a CYP2C8/2C9 substrate, and the linkage disequilibrium that exists between these genes. In terms of adverse effects, some data suggest that the combined presence of CYP2C8*3 and CYP2C9*2 is a determinant of NSAID-induced gastrointestinal bleeding [Article:18216720]. Additional studies are needed to delineate the relative contributions of CYP2C8 versus CYP2C9 to the metabolism of various NSAIDS, and the ability of common CYP2C8/2C9 haplotypes to predict NSAID efficacy and/or toxicity [Article:19422321].

Other Clinical Associations
Bisphosphonates (e.g., zoledronic acid) are used commonly in the treatment of benign and malignant bone diseases. However, these agents are associated with the rare, but serious, adverse effect of jawbone necrosis. A genome-wide association study found an intronic CYP2C8 SNP (rs1934951) to be significantly associated with osteonecrosis of the jaw in multiple myeloma patients treated with bisphosphonate therapy [Article:18594024]. Bisphosphonates are not metabolized by cytochrome P450 enzymes; therefore the mechanism underlying this association is unclear, but may be due to the influence of CYP2C8 on vascular tone, angiogenesis, and/or inflammation. However, other studies in different patient populations have not been able to replicate the genome-wide association study findings [Articles:21151627, 21685474, 21396799]. As such, additional clinical and mechanistic work is needed to determine if CYP2C8 SNPs are predictors of bisphosphonate-related osteonecrosis of the jaw.

Calcineurin inhibitors (i.e., cyclosporine, tacrolimus) are key agents used to prevent allograft rejection in solid organ transplantation; however, they are associated with a high incidence of renal dysfunction. Data suggest that CYP2C8 polymorphisms may influence the risk of renal dysfunction in liver and kidney transplant patients treated with these agents. One study reported that CYP2C8*3 was a predictor of renal toxicity in liver transplant patients treated with calcineurin inhibitors, particularly tacrolimus [Article:18769365]. CYP2C8 is responsible for the metabolism of endogenous arachidonic acid to vasodilatory expoxyeicosatrienoic acid (EET) metabolites, which are thought to have protective functions in the kidney. It is hypothesized that diminished 14,15-EET and 11,12-EET production, as a result of CYP2C8*3, may predispose individuals to calcineurin inhibitor nephrotoxicity [Article:18769365]. Similar findings have recently been observed in renal transplant recipients [Article:23426640]. In terms of other immunosuppressant agents, studies have reported that CYP2C8 SNPs rs11572103 (*2) and rs11572076 were significantly associated with mycophenolate-related anemia following kidney transplantation [Articles:21107304, 22572835].

Conclusion
CYP2C8 plays a major role in the metabolism of many commonly used drugs and several CYP2C8 SNPs have functional consequence in vivo. As a result, CYP2C8 has emerged as a significant pharmacogene. CYP2C8 genotype may be important in determining the dosage and/or selection of drugs to optimize efficacy and reduce adverse drug reactions. Additional clinical studies are needed to further elucidate the impact and clinical significance of key CYP2C8 variants and haplotypes on heterogeneity in drug disposition and response phenotypes in humans.

Citation PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenetics and genomics. 2013. Aquilante Christina L, Niemi Mikko, Gong Li, Altman Russ B, Klein Teri E. PubMed
History

Submitted by Christina L. Aquilante, Mikko Niemi, Li Gong, Russ B. Altman, Teri E. Klein

Variant Summaries rs10509681, rs1058930, rs11572080, rs11572103, rs17110453, rs7909236
Haplotype Summaries CYP2C8 *1B, CYP2C8 *2, CYP2C8 *4, CYP2C8 *1C, CYP2C8 *3
Drugs

Haplotype Overview

Haplotypes are derived from the Human Cytochrome P450 (CYP) Allele Nomenclature Database, 5/16/2012. The Human Cytochrome P450 (CYP) Allele Nomenclature Database states that nucleotide changes listed below are based on NCBI Reference Sequence NC_000010.9. Note that the nucleotide positions from the Human Cytochrome P450 (CYP) Allele Nomenclature Database do not directly match the given NCBI reference sequence. For questions about nucleotide positions, please contact the Human Cytochrome P450 (CYP) Allele Nomenclature Database directly, as they are the authoritative source on cytochrome P450 nomenclature.

Source: PharmGKB

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Anti-diabetic Drug Repaglinide Pathway, Pharmacokinetics
    Repaglinide metabolism and transport in a liver cell.
  1. Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Caffeine Pathway, Pharmacokinetics
    Stylized liver cell showing candidate genes involved in the metabolism of caffeine.
  1. Carbamazepine Pathway, Pharmacokinetics
    Stylized liver cell depicting candidate genes involved in the pharmacokinetics of carbamazepine.
  1. Cyclophosphamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of cyclophosphamide.
  1. Erlotinib Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the transportation and metabolism of Erlotinib.
  1. Fluvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Ibuprofen Pathway, Pharmacokinetics
    Stylized diagram of metabolism and transport of ibuprofen in the liver and kidney.
  1. Ifosfamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of ifosfamide.
  1. Mycophenolic acid Pathway, Pharmacokinetics/Pharmacodynamics
    Schematic representation of mycophenolic acid metabolism.
  1. Phenytoin Pathway, Pharmacokinetics
    Genes involved in the metabolism of phenytoin in the human liver cell.
  1. Rosiglitazone Pharmacokinetic Pathway
    Rosiglitazone is transported from hepatic sinusoids into hepatocytes -- a process mediated by the organic anion transporting polypeptide, where is is metabolized by cytochrome p450 2C8 and 2C9.
  1. Statin Pathway - Generalized, Pharmacokinetics
    Representation of the superset of all genes involved in the transport, metabolism and clearance of statin class drugs.
  1. Taxane Pathway, Pharmacokinetics
    Representation of the genes involved in the metabolism and transport of paclitaxel and docetaxel, and the downstream effects of the drugs.
  1. Warfarin Pathway, Pharmacokinetics
    Representation of the candidate genes involved in transport, metabolism and clearance of warfarin.

External Pathways

Links to non-PharmGKB pathways.

  1. Xenobiotics - (Reactome via Pathway Interaction Database)

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
NR1I2

Curated Information ?

Curated Information ?

Publications related to CYP2C8: 142

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics. 2014. Gentile Giovanna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An atlas of genetic influences on human blood metabolites. Nature genetics. 2014. Shin So-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics. 2014. Brown Andrew Mk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast cancer research and treatment. 2014. Hertz Daniel L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenetics and genomics. 2014. Woillard Jean-Baptiste, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2014. Lowenberg Daniella, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine. Pharmacogenomics. 2014. Polimanti Renato, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC. Cardiovascular interventions. 2013. Viviani Anselmi Chiara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Clinical pharmacology and therapeutics. 2013. Filppula A M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C8*2 on the Pharmacokinetics of Pioglitazone in Healthy African-American Volunteers. Pharmacotherapy. 2013. Aquilante Christina L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib. Journal of clinical pharmacology. 2013. Prieto-Pérez Rocío, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenetics and genomics. 2013. Aquilante Christina L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications. European journal of clinical pharmacology. 2013. Yiannakopoulou Eugenia. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The role of CYP2C8 genotypes in dose requirement and levels of everolimus after heart transplantation. Wiener klinische Wochenschrift. 2013. Kniepeiss Daniela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Malaria pharmacogenomics: return to the future. Pharmacogenomics. 2013. Gil Jp. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. Journal of clinical pharmacology. 2013. Gervasini Guillermo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide, and ibuprofen enantiomers in vitro. Biopharmaceutics & drug disposition. 2013. Yu Lushan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013. Hertz D L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARgamma on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenetics and genomics. 2013. Stage Tore B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. British journal of clinical pharmacology. 2013. Aquilante Christina L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics. 2013. Hassan Moustapha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. European journal of clinical pharmacology. 2012. Pedersen Rasmus Steen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: phenytoin pathway. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast cancer research and treatment. 2012. Hertz Daniel L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. The pharmacogenomics journal. 2012. Martis S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: caffeine pathway. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics. 2012. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica. 2011. Such Esperanza, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochemical pharmacology. 2011. Kaspera Rüdiger, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. European journal of clinical pharmacology. 2011. Bergmann Troels K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8. Amino acids. 2011. Jiang Hualin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro investigation of the glutathione S-transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals. 2011. Usui Toru, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. The pharmacogenomics journal. 2011. Bergmann T K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans. Clinical pharmacology and therapeutics. 2011. Honkalammi J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Global patterns of genetic diversity and signals of natural selection for human ADME genes. Human molecular genetics. 2011. Li Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation. 2011. Jacobson Pamala A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. European journal of clinical pharmacology. 2010. Pedersen Rasmus S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. The pharmacogenomics journal. 2010. Suarez-Kurtz G, et al. PubMed
Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis. Pharmacogenetics and genomics. 2010. Kaspera Rüdiger, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expectations, validity, and reality in pharmacogenetics. Journal of clinical epidemiology. 2010. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of osteoporosis-related bone fractures: moving towards the harmonization and validation of polymorphism diagnostic tools. Pharmacogenomics. 2010. Rojo Venegas Karen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clinical pharmacology and therapeutics. 2010. Karonen T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variance in CYP2C8 and increased risk of myocardial infarction. Pharmacogenetics and genomics. 2010. Rodenburg Eline M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics. 2010. Grover Sandeep, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions. Xenobiotica; the fate of foreign compounds in biological systems. 2010. Gao Yiwen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharmaceutics & drug disposition. 2010. Zhou Lin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clinical pharmacokinetics. 2010. Staatz Christine E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. The pharmacogenomics journal. 2010. Leskelä S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. The pharmacogenomics journal. 2010. Edvardsen H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic & clinical pharmacology & toxicology. 2009. Muschler Eugen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochemical pharmacology. 2009. Zharikova Olga L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Taxane Pathway. Pharmacogenetics and genomics. 2009. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. The Lancet infectious diseases. 2009. Kerb Reinhold, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Therapeutics and clinical risk management. 2010. English Bevin C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Current drug metabolism. 2009. Lai Xin-Sheng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Amodiaquine-associated adverse effects after inadvertent overdose and after a standard therapeutic dose. Ghana medical journal. 2009. Adjei G O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009. Daily Elizabeth B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. The Laryngoscope. 2009. Grau Juan J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Global variation in CYP2C8-CYP2C9 functional haplotypes. The pharmacogenomics journal. 2009. Speed William C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?. Expert opinion on drug metabolism & toxicology. 2009. Agúndez José A G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Pharmacogenomics. 2009. Mehlotra Rajeev K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic & clinical pharmacology & toxicology. 2009. Gréen Henrik, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrobial agents and chemotherapy. 2008. Adjei George O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC medical genetics. 2009. Kudzi William, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical therapeutics. 2008. Deremer David L, et al. PubMed
Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenetics and genomics. 2008. Smith Helen E, et al. PubMed
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008. Sarasquete Maria E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. European journal of clinical pharmacology. 2008. Dorado P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Amodiaquine pharmacogenetics. Pharmacogenomics. 2008. Gil Jose Pedro. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clinical pharmacology and therapeutics. 2008. Tornio A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Human genomics. 2008. Aquilante Christina L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. Biochemical pharmacology. 2008. Kot Marta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug metabolism and disposition: the biological fate of chemicals. 2008. Pearce Robin E, et al. PubMed
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. The pharmacogenomics journal. 2008. Rodríguez-Antona C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacological research : the official journal of the Italian Pharmacological Society. 2008. López-Rodríguez Rosario, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenetics and genomics. 2008. Marciante Kristin D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro. Drug metabolism and disposition: the biological fate of chemicals. 2008. Chang Shu-Ying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics. 2008. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug metabolism and disposition: the biological fate of chemicals. 2008. Tornio Aleksi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenetics and genomics. 2008. Blanco Gerardo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacology of artemisinin-based combination therapies. Clinical pharmacokinetics. 2008. German Polina I, et al. PubMed
Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug metabolism and pharmacokinetics. 2008. Singh Rajinder, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug metabolism and disposition: the biological fate of chemicals. 2007. Hiratsuka Masahiro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Marsh Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. The pharmacogenomics journal. 2007. Marsh S, et al. PubMed
Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clinical pharmacology and therapeutics. 2007. Parikh S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. American journal of human genetics. 2007. Liu Fan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenetics and genomics. 2007. Saito Yoshiro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of paclitaxel metabolism. Critical reviews in oncology/hematology. 2007. Spratlin Jennifer, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C8 and antimalaria drug efficacy. Pharmacogenomics. 2007. Gil J P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007. Daly Ann K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. British journal of clinical pharmacology. 2006. Pedersen Rasmus S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clinical pharmacology and therapeutics. 2006. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Molecular diagnosis & therapy. 2007. Bozkurt Ozlem, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. Neuromolecular medicine. 2007. Martínez Carmen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. Pharmacogenomics. 2006. García-Martín Elena, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic & clinical pharmacology & toxicology. 2006. Jaakkola Tiina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical pharmacology and therapeutics. 2006. Neuvonen Pertti J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clinical pharmacology and therapeutics. 2006. Kajosaari Lauri I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of rifampicin on the pharmacokinetics of pioglitazone. British journal of clinical pharmacology. 2006. Jaakkola Tiina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphism discovery in 51 chemotherapy pathway genes. Human molecular genetics. 2005. Freimuth Robert R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Investigational new drugs. 2005. van Schaik Ron H N. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genotyping for cytochrome P450 polymorphisms. Methods in molecular biology (Clifton, N.J.). 2006. Daly Ann K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450s and other enzymes in drug metabolism and toxicity. The AAPS journal. 2006. Guengerich F Peter. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Tropical medicine & international health : TM & IH. 2005. Röwer Susanne, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. Henningsson Anja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysian Indians. Journal of clinical pharmacy and therapeutics. 2005. Muthiah Y D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Molecular pharmacology. 2005. Ferguson Stephen S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. Journal of clinical pharmacology. 2005. Nakajima Miki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clinical pharmacology and therapeutics. 2005. Totah Rheem A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug metabolism and disposition: the biological fate of chemicals. 2005. Hichiya Hiroyuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. British journal of clinical pharmacology. 2005. Martínez Carmen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. British journal of clinical pharmacology. 2005. Hruska M W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clinical pharmacokinetics. 2005. Kosoglou Teddy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. Journal of pharmacological sciences. 2005. Taniguchi Ryoko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clinical pharmacology and therapeutics. 2004. García-Martín Elena, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. The Journal of biological chemistry. 2004. Schoch Guillaume A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. Journal of human genetics. 2004. Ishikawa Chikako, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 2003. Yasar Umit, et al. PubMed
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clinical pharmacology and therapeutics. 2003. Niemi Mikko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. British journal of clinical pharmacology. 2003. Prueksaritanont Thomayant, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2003. Madan Ajay, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual review of pharmacology and toxicology. 2003. Ding Xinxin, et al. PubMed
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochemical pharmacology. 2002. Bahadur Namrata, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacology & toxicology. 2002. Soyama Akiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2002. Rae James M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug metabolism and disposition: the biological fate of chemicals. 2002. Cresteil Thierry, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. The Journal of pharmacology and experimental therapeutics. 2002. Li Xue-Qing, et al. PubMed
Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biological & pharmaceutical bulletin. 2001. Soyama A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug metabolism and pharmacokinetics. 2002. Soyama Akiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. The Journal of pharmacology and experimental therapeutics. 2001. Rae J M, et al. PubMed
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001. Dai D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacokinetics of fluvastatin. Clinical pharmacokinetics. 2001. Scripture C D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2000. Komatsu T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archives of toxicology. 1999. Yamazaki H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. Journal of biochemical and molecular toxicology. 1999. Klose T S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994. Goldstein J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. The Journal of biological chemistry. 1994. de Morais S M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Molecular pharmacology. 1994. Relling M V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clinical pharmacology and therapeutics. 1991. Skjelbo E, et al. PubMed

LinkOuts

ALFRED:
LO004214L
HuGE:
CYP2C8
Comparative Toxicogenomics Database:
1558
ModBase:
P10632
HumanCyc Gene:
HS06459
HGNC:
2622

Common Searches